Kim D.  Blickenstaff net worth and biography

Kim Blickenstaff Biography and Net Worth

Mr. Blickenstaff currently serves as Chair of our board of directors following his transition from the Executive Chair role in March 2020. Prior to serving as Executive Chair, Mr. Blickenstaff served as our President and Chief Executive Officer from September 2007 to March 2019. He has been a member of our board of directors since September 2007. Prior to joining us, Mr. Blickenstaff served as Chair and Chief Executive Officer of Biosite Incorporated, a provider of medical diagnostic products, from 1988 until its acquisition by Inverness Medical Innovations, Inc. in June 2007. Mr. Blickenstaff previously served as a director of Medivation, Inc., a biotechnology company, from 2005 to 2016, until its acquisition by Pfizer, and as a director of DexCom, Inc. (Nasdaq: DXCM), a provider of continuous glucose monitoring systems, from June 2001 to September 2007. Mr. Blickenstaff serves as a director and member of the compensation and audit committees of Nuvation Bio Inc. (NYSE: NUVB), an oncology biopharmaceutical therapy company. Mr. Blickenstaff was formerly a certified public accountant and has more than 20 years of experience overseeing the preparation of financial statements. He holds a B.A. in Political Science from Loyola University, Chicago, and an M.B.A. from the Graduate School of Business, Loyola University, Chicago.

What is Kim D. Blickenstaff's net worth?

The estimated net worth of Kim D. Blickenstaff is at least $7.30 million as of May 17th, 2022. Mr. Blickenstaff owns 205,190 shares of Tandem Diabetes Care stock worth more than $7,296,556 as of April 25th. This net worth evaluation does not reflect any other assets that Mr. Blickenstaff may own. Learn More about Kim D. Blickenstaff's net worth.

How do I contact Kim D. Blickenstaff?

The corporate mailing address for Mr. Blickenstaff and other Tandem Diabetes Care executives is 11075 ROSELLE STREET, San Diego CA, 92121. Tandem Diabetes Care can also be reached via phone at (858) 366-6900 and via email at [email protected]. Learn More on Kim D. Blickenstaff's contact information.

Has Kim D. Blickenstaff been buying or selling shares of Tandem Diabetes Care?

Kim D. Blickenstaff has not been actively trading shares of Tandem Diabetes Care within the last three months. Most recently, Kim D. Blickenstaff sold 10,762 shares of the business's stock in a transaction on Tuesday, May 17th. The shares were sold at an average price of $92.91, for a transaction totalling $999,897.42. Following the completion of the sale, the director now directly owns 205,190 shares of the company's stock, valued at $19,064,202.90. Learn More on Kim D. Blickenstaff's trading history.

Who are Tandem Diabetes Care's active insiders?

Tandem Diabetes Care's insider roster includes David Berger (EVP), Kim Blickenstaff (Director), Elizabeth Gasser (EVP), Brian Hansen (EVP), James Leal (SVP), Kathleen McGroddy-Goetz (Director), Susan Morrison (EVP), Rebecca Robertson (Director), John Sheridan (CEO), Christopher Twomey (Director), and Leigh Vosseller (CFO). Learn More on Tandem Diabetes Care's active insiders.

Are insiders buying or selling shares of Tandem Diabetes Care?

In the last twelve months, Tandem Diabetes Care insiders bought shares 6 times. They purchased a total of 27,150 shares worth more than $635,045.95. The most recent insider tranaction occured on November, 27th when Director Dick Allen bought 5,000 shares worth more than $94,800.00. Insiders at Tandem Diabetes Care own 2.5% of the company. Learn More about insider trades at Tandem Diabetes Care.

Information on this page was last updated on 11/27/2023.

Kim D. Blickenstaff Insider Trading History at Tandem Diabetes Care

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/17/2022Sell10,762$92.91$999,897.42205,190View SEC Filing Icon  
8/12/2021Sell13,990$105.50$1,475,945.001,892View SEC Filing Icon  
8/10/2021Sell3,210$107.21$344,144.101,892View SEC Filing Icon  
3/16/2021Sell200,000$87.27$17,454,000.00
12/15/2020Sell13,598$92.48$1,257,543.04View SEC Filing Icon  
12/11/2020Sell9,150$93.00$850,950.00View SEC Filing Icon  
12/9/2020Sell15,850$94.91$1,504,323.50View SEC Filing Icon  
12/1/2020Sell25,000$97.01$2,425,250.001,500View SEC Filing Icon  
11/12/2020Sell16,802$106.88$1,795,797.76View SEC Filing Icon  
8/18/2020Sell38,250$103.49$3,958,492.50View SEC Filing Icon  
8/10/2020Sell8,882$103.88$922,662.16View SEC Filing Icon  
8/7/2020Sell161,244$106.23$17,128,950.12View SEC Filing Icon  
6/30/2020Sell50,000$95.57$4,778,500.00View SEC Filing Icon  
1/29/2020Sell50,000$75.92$3,796,000.00View SEC Filing Icon  
12/16/2019Sell200,000$59.85$11,970,000.00View SEC Filing Icon  
8/29/2019Sell100,000$70.96$7,096,000.00View SEC Filing Icon  
3/11/2019Sell200,000$64.95$12,990,000.00View SEC Filing Icon  
11/7/2018Sell198,000$37.01$7,327,980.00View SEC Filing Icon  
2/9/2018Buy750,000$2.00$1,500,000.00View SEC Filing Icon  
10/13/2017Buy285,700$3.50$999,950.00View SEC Filing Icon  
3/23/2017Buy1,600,000$1.25$2,000,000.002,007,939View SEC Filing Icon  
See Full Table

Kim D. Blickenstaff Buying and Selling Activity at Tandem Diabetes Care

This chart shows Kim D Blickenstaff's buying and selling at Tandem Diabetes Care by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Tandem Diabetes Care Company Overview

Tandem Diabetes Care logo
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $35.56
Low: $34.91
High: $36.27

50 Day Range

MA: $30.51
Low: $22.55
High: $35.41

2 Week Range

Now: $35.56
Low: $13.82
High: $40.74

Volume

1,567,824 shs

Average Volume

1,733,324 shs

Market Capitalization

$2.30 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.12